Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol-Myers Squibb is conducting a study titled ‘A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy.’ The study aims to assess the effectiveness and safety of ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis.
The intervention being tested is ozanimod, an oral drug intended to help pediatric patients with ulcerative colitis who have not responded adequately to conventional treatments. The study involves administering specified doses of ozanimod to participants.
The study design is interventional, with a randomized allocation and a parallel intervention model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose of the study is treatment.
The study began on May 30, 2022, and is currently recruiting participants. The last update was submitted on June 30, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Bristol-Myers Squibb’s stock performance and investor sentiment, especially if ozanimod proves effective. Success in this study could position the company favorably against competitors in the ulcerative colitis treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.